Bone Metastases News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

New Model Provides Long Bone Metastases Prognostic Model - Monthly Prescribing Reference



New Model Provides Long Bone Metastases Prognostic Model 
Monthly Prescribing Reference
HealthDay News ? A model with 4 categories has been developed to stratify patients with symptomatic long bone metastases (LBM) based on their expected survival, according to an article published online February 7 in the Journal of Bone & Joint Surgery ...

 


Cabozantinib Improves Survival in RCC Patients With Bone Metastases - OncLive



OncLive
 
Cabozantinib Improves Survival in RCC Patients With Bone Metastases 
OncLive
Cabozantinib (Cabometyx) was associated with an 8-month improvement in overall survival (OS) and a 4.7-month improvement in progression-free survival (PFS) compared with everolimus (Afinitor) in pretreated patients with advanced renal cell carcinoma ...

and more » 


Osteomimicry May Contribute to Uptake of Radium-223 Within Bone Metastases for Patients With mCRPC - AJMC.com Managed Markets Network



Osteomimicry May Contribute to Uptake of Radium-223 Within Bone Metastases for Patients With mCRPC 
AJMC.com Managed Markets Network
Osteomimicry may contribute to the uptake of radium-223 within bone metastases and may subsequently enhance the therapeutic benefit of radium-223, according to an abstract presented by Andrew Armstrong, MD, associate professor of medicine, Duke ...
ASCO GU 2018: Genomic and Phenotypic Evidence for Prostate Cancer Osteomimicry in Circulating Tumor Cells from ... UroToday

all 2 news articles » 


Cabozantinib Superior to Everolimus in Treatment of RCC Patients With Bone Metastases - Targeted Oncology



Targeted Oncology
 
Cabozantinib Superior to Everolimus in Treatment of RCC Patients With Bone Metastases 
Targeted Oncology
According to results of a subgroup analysis of the phase III METEOR trial, cabozantinib (Cabometyx) demonstrated a 4.7 month improvement in progression-free survival (PFS) compared with everolimus (Afinitor) in pretreated patients with advanced renal ...

 


The relationship between local recurrences and distant metastases in prostate cancer: can11C-choline PET/CT ... - UroToday



The relationship between local recurrences and distant metastases in prostate cancer: can11C-choline PET/CT ... 
UroToday
On the contrary, the frequency of lymph node metastases (overall rate in the 0-16 years interval after prostatectomy: 26.3%) and of bone metastases (overall rate: 13.8%) decreased significantly over time. Kaplan-Meier curves showed no significant group ...

 


Simple tool can help doctors estimate survival for patients with long bone metastases - News-Medical.net



News-Medical.net
 
Simple tool can help doctors estimate survival for patients with long bone metastases 
News-Medical.net
A simple three-factor tool can help doctors estimate survival time in patients with long bone metastases (LBMs)- advanced cancer that has spread to the bones of the limbs, reports a study in the February 7, 2018, issue of The Journal of Bone & Joint ...

 


Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the ... - UroToday



Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the ... 
UroToday
Bone metastases commonly occur in conjunction with solid tumors, and are associated with serious bone complications. Population-based estimates of bone metastasis incidence are limited, often based on autopsy data, and may not reflect current treatment ...

 


Israel Ministry of Health Includes INSIGHTEC's Focused Ultrasound Treatment for Medication-Refractory Essential ... - PR Newswire (press release)



Israel Ministry of Health Includes INSIGHTEC's Focused Ultrasound Treatment for Medication-Refractory Essential ... 
PR Newswire (press release)
INSIGHTEC is the world leader and innovator of MRI-guided Focused Ultrasound. The company's non-invasive therapy platforms, Exablate and Exablate Neuro, are proven technology based on sound clinical evidence for treating essential tremor, painful bone ...

and more » 


Bone Markers Can Predict Bone-Specific Recurrence in Early Breast Cancer - Cancer Network



Bone Markers Can Predict Bone-Specific Recurrence in Early Breast Cancer 
Cancer Network
Several markers of bone formation and resorption were found to be predictive of bone-specific recurrence in patients with early breast cancer, according to a new study. ?Bone metastases ultimately affect more than two-thirds of patients with advanced ...

 


ASCO GU 2018: Radium-223 Retreatment in an International, Open-label, Phase I/II Study in Patients with CRPC and ... - UroToday



ASCO GU 2018: Radium-223 Retreatment in an International, Open-label, Phase I/II Study in Patients with CRPC and ... 
UroToday
For this trial, 44 patients with CRPC and bone metastases who completed six initial Ra-223 injections with no disease progression in bone and later progressed were eligible for Ra-223 re-treatment (six additional Ra-223 injections), provided that ...